Teva Pharmaceutical Industries Limited (TEVA) Leerink's 2025 Global Healthcare Conference (Transcript)Seeking Alpha • 03/12/25
Teva Pharmaceutical Industries Limited (TEVA) Presents at Barclays 27th Annual Global Healthcare Conference (Transcript)Seeking Alpha • 03/11/25
Teva to Present at Barclays Global Healthcare Conference and Leerink Partners Global Healthcare Conferences in MarchGlobeNewsWire • 03/03/25
2025 Community Routes: Access to Mental Health Care Grants Awarded to Clinics in Alabama, Mississippi, and Texas, Funded by Teva PharmaceuticalsGlobeNewsWire • 02/27/25
Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY(R) (risperidone) Extended-Release Injectable Suspension as a Treatment for Patients with Bipolar I DisorderGlobeNewsWire • 02/25/25
Teva Pharmaceutical Industries Limited (TEVA) Duvakitug (Anti-TL1A) Phase 2 Investors Call to Discuss New Data Presented at ECCO Conference (Transcript)Seeking Alpha • 02/24/25
Teva and Sanofi Present New Positive Phase 2b Study Results at ECCO 2025 Reinforcing Best-in-Class Potential of Duvakitug (Anti-TL1A) in Ulcerative Colitis and Crohn's DiseaseGlobeNewsWire • 02/22/25
Billionaire Stanley Druckenmiller Dumped Duquesne's Entire Stake in Broadcom and Bought One of Wall Street's Hottest Drug Stocks Hand Over FistThe Motley Fool • 02/20/25
Teva to Host Conference Call on February 24, 2025 to Discuss New Data Presented for Duvakitug (anti-TL1A) Positive Phase 2b results at the 20th Annual Congress of the European Crohn's and Colitis Organisation (ECCO)GlobeNewsWire • 02/18/25
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's EyleaInvestopedia • 02/18/25
Alvotech and Teva Announce Filing Acceptance of U.S. Biologics License Application for AVT06, a Proposed Biosimilar to Eylea® (aflibercept)GlobeNewsWire • 02/18/25
Axsome Settling Teva Patent Litigation Is Another Positive Catalyst -- UpgradeSeeking Alpha • 02/11/25
Axsome Therapeutics Resolves Generic Patent Litigation With Teva Over Depression Drug, Analyst Maintains Axsome As 'Top Pick For 2025'Benzinga • 02/10/25
Completion of the Pivotal Phase 3 Trial for Olanzapine LAI in Schizophrenia Conducted by Teva PharmaceuticalsBusiness Wire • 02/10/25
Teva Pharmaceutical: 2025 Guidance Sinks The Stock, But Presents An OpportunitySeeking Alpha • 01/30/25
TEVA Stock Down 14% Despite Q4 Earnings & Revenues Beat EstimatesZacks Investment Research • 01/30/25
Teva Pharmaceutical Industries Limited (TEVA) Q4 2024 Earnings Conference Call TranscriptSeeking Alpha • 01/29/25